Results 181 to 190 of about 1,232,228 (310)
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
Hepatocellular carcinoma drug resistance models. [PDF]
Cancer Cell IntXie X +5 more
europepmc +1 more source
Identifying prognostic targets in metastatic prostate cancer beyond AR
FEBS Open Bio, EarlyView.Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng +13 more
wiley +1 more source
Lactylation: a novel driver of drug resistance in the tumor microenvironment. [PDF]
Cancer Drug ResistLi C, Liu Z, Kong D, Li Z, Li L.
europepmc +1 more source
Current trends in single‐cell RNA sequencing applications in diabetes mellitus
FEBS Open Bio, EarlyView.Single‐cell RNA sequencing is a powerful approach to decipher the cellular and molecular landscape at a single‐cell resolution. The rapid development of this technology has led to a wide range of applications, including the detection of cellular and molecular mechanisms and the identification and introduction of novel potential diagnostic and ...
Seyed Sajjad Zadian +6 more
wiley +1 more source
Epigenetic modification of cuproptosis by non-coding RNAs in cancer drug resistance. [PDF]
Mol CancerDu F +6 more
europepmc +1 more source